Clinical Trials

GSK, Innoviva’s Trelegy Ellipta meets primary endpoint in phase III asthma study

GlaxoSmithKline (GSK) and Innoviva’s respiratory drug Trelegy Ellipta has met primary endpoint in the phase III CAPTAIN (clinical study of asthma patients receiving triple therapy through a single inhaler) study.

Exelixis initiates phase 3 trial of cabozantinib in advanced renal cell carcinoma

Exelixis, Inc. today announced that it is initiating COSMIC-313, a phase 3 pivotal trial of cabozantinib (CABOMETYX) in combination with nivolumab (Opdivo) and ipilimumab (Yervoy) versus nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell Carcinoma Database Consortium.

Navidea announces comparative study to evaluate tilmanocept in patients with TB

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Professor Mike Sathekge, MBChB, M. Med (Nuclear Medicine), PhD Professor and Head of the Department of Nuclear Medicine in the Faculty of Health Sciences at the University of Pretoria/Steve Biko Academic Hospital, plans to initiate a comparative study evaluating the use of Tilmanocept in patients with TB.

Merck’s Keytruda yields mixed results in phase 3 KEYNOTE-062 trial

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced topline findings from the final analysis of the pivotal Phase 3 KEYNOTE-062 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy and in combination with chemotherapy (cisplatin and either 5-fluorouracil or capecitabine) for the first-line treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Gilead’s selonsertib fails to meet primary endpoint in Phase 3 NASH study

Gilead Sciences’ selonsertib has failed to achieve primary end point in the Phase 3 study of nonalcoholic steatohepatitis (NASH).

Teva to discontinue ENFORCE program for fremanezumab due to futility

Teva Pharmaceutical Industries said that it will stop an ongoing clinical development program of its humanized monoclonal antibody fremanezumab in cluster headaches due to futility.

Lilly’s Taltz meets primary endpoint in phase 3 nr-axSpA trial

Eli Lilly and Company (Lilly) has announced that its psoriatic arthritis drug Taltz (ixekizumab) succeeded in a phase 3 trial in patients with non-radiographic axial spondyloarthritis (nr-axSpA).

Forbius announces first patient dosed in phase 2a EGFR-overexpressing TNBC trial of AVID100

Forbius, a clinical-stage company that develops novel biologics for the treatment of cancer and fibrosis, announced that the first patient has been dosed in a Phase 2a triple negative breast cancer (TNBC) clinical trial with AVID100, a novel, tumor-specific anti-epidermal growth factor receptor (EGFR) antibody-drug conjugate (ADC).

Pfizer, Lilly’s painkiller tanezumab shows mixed results in phase 3 osteoarthritis trial

Pfizer and Eli Lilly’s phase 3 study has showed mixed results of painkiller tanezumab in the treatment of patients with osteoarthritis (OA).